Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Receivables (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Receivables for 17 consecutive years, with $11.6 billion as the latest value for Q4 2025.

  • Quarterly Receivables fell 7.02% to $11.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.6 billion through Dec 2025, down 7.02% year-over-year, with the annual reading at $11.6 billion for FY2025, 7.02% down from the prior year.
  • Receivables for Q4 2025 was $11.6 billion at Bristol Myers Squibb, roughly flat from $11.6 billion in the prior quarter.
  • The five-year high for Receivables was $13.1 billion in Q2 2025, with the low at $9.5 billion in Q2 2022.
  • Average Receivables over 5 years is $11.4 billion, with a median of $11.5 billion recorded in 2024.
  • The sharpest move saw Receivables rose 27.72% in 2023, then decreased 11.42% in 2024.
  • Over 5 years, Receivables stood at $9.7 billion in 2021, then increased by 19.43% to $11.6 billion in 2022, then rose by 11.52% to $13.0 billion in 2023, then decreased by 3.69% to $12.5 billion in 2024, then fell by 7.02% to $11.6 billion in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $11.6 billion, $11.6 billion, and $13.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.